I 117th CONGRESS 1st Session H. R. 4292 IN THE HOUSE OF REPRESENTATIVES June 30, 2021 Ms. Velázquez (for herself, Mr. Katko , Mr. Pascrell , Ms. Johnson of Texas , Mrs. Carolyn B. Maloney of New York , Mr. Tonko , Ms. Clarke of New York , Ms. Sewell , Mr. Carson , Mr. Suozzi , Ms. Meng , Mr. Higgins of New York , Mr. Allred , Mr. Veasey , Ms. Ross , Mrs. Fletcher , and Mr. Sires ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To provide for the establishment of COVID–19 and pandemic response centers of excellence, and for other purposes.

1. Short title This Act may be cited as the COVID–19 and Pandemic Response Centers of Excellence Act . 2. COVID–19 and pandemic response centers of excellence (a) In general Not later than 90 days after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this Act as the Secretary ) shall award grants, contracts, or cooperative agreements to academic medical centers for the establishment or continued support of not less than 10 centers of excellence to address issues associated with— (1) COVID–19, including— (A) testing and diagnostics, including availability and accessibility; (B) patient care, including related follow-up care for COVID–19 survivors; (C) best practices in the use of supplies and therapeutics; (D) mental health treatment of frontline health care workers and other caregivers; (E) health, health care disparities, and best practices for promoting health equity; (F) research; and (G) education and training, including for health professionals, scientists, and communities; and (2) future pandemic preparedness and response, including— (A) the priorities specified in paragraph (1); (B) working in a coordinated fashion with the advisory committee established under subsection (c) and respective State and local health authorities for the purposes of disseminating information, best practices, and other such public health-related measures; and (C) readiness to conduct or contribute to basic, clinical, translational, and implementation research into novel or existing public health threats, such as participating in diverse clinical trial research or vaccine, diagnostic, or therapeutic development, however appropriate. (b) Eligibility To be eligible to receive a grant, contract, or cooperative agreement under subsection (a), an entity shall— (1) be an academic medical center; and (2) submit to the Secretary of Health and Human Services an application at such time, in such manner, and containing such information as the Secretary may require, including a description of— (A) how the entity will conduct or contribute to the activities described in such subsection; (B) how many individuals with COVID–19 the entity has cared for and the entity’s continued capacity and expertise to provide such care, and how the entity improves health outcomes for such individuals, and reduces health inequities among such individuals; (C) how the entity plans to comprehensively care for COVID–19 survivors; (D) how the entity identifies and addresses the mental health needs of the frontline health care workforce to ensure the ability of such individuals to continue to care for the community, in addition to current and future COVID–19 patients; (E) how the entity will conduct research and address health and health care inequities by identifying, implementing, or developing COVID–19 evidenced-based strategies and interventions and engaging the populations heavily impacted by COVID–19 in their community; (F) how the entity will engage with the community and share information concerning COVID–19 basic, clinical, translational, and implementation research, including vaccine research; (G) the most significant risk factors and comorbidities of COVID–19 patients observed by the entity and strategies employed by the entity to reduce the risk of COVID–19 transmission; (H) the long-term health effects of COVID–19 and effective treatments utilized by the entity to treat those infected with COVID–19; (I) secondary factors in COVID–19 mobility and mortality identified by the entity, such as antibiotic resistant infections and blood clotting disorders; (J) how the entity will collaborate with other health care institutions, public health agencies, and community-based organizations to ensure equitable care to marginalized and underserved populations, including rural and ethnic minority communities; (K) how the entity will conduct research involving the unique pathophysiology of COVID–19 in children and adolescents and unique needs of pregnant women; and (L) how the entity is prepared to contribute to advance planning and real-time response efforts for subsequent outbreaks that present a significant potential to imminently become a national public health emergency. (c) Advisory committee (1) In general Not later than 1 year after the date of enactment of this Act, the Secretary shall establish an advisory committee to facilitate collaboration, information sharing, and the dissemination of best practices relating to the COVID–19 pandemic, in addition to preparing for, monitoring, mitigating, and responding to future pandemics. The advisory committee shall be composed of a designee of each of the following: (A) The Director of the Centers for Disease Control and Prevention. (B) The Director of the National Institutes of Health. (C) The Commissioner of Food and Drugs. (D) The Assistant Secretary for Preparedness and Response. (E) The Director of the Biomedical Advanced Research and Development Authority. (F) The Secretary of Defense. (G) A representative from each center of excellence established under this section. (H) Not more than 20 representatives from national organizations that work with and can represent populations disproportionately impacted by COVID–19, populations vulnerable for disproportionate impact during a subsequent pandemic, and populations disproportionately impacted by other health disparities. (2) Meetings The advisory committee under paragraph (1) shall convene not less than twice annually. (3) Votes In carrying out its duties pursuant to section 9 of the Federal Advisory Committee Act (5 U.S.C. App.), the advisory committee shall vote on which best practices with respect to COVID–19 and pandemic response to disseminate. (d) COVID–19 and pandemic response centers of excellence program fund (1) Establishment of fund There is established a fund to be known as the COVID–19 and Pandemic Response Centers of Excellence Program Fund (referred to in this section as the Fund ) to provide awards under this section. (2) Appropriations Out of any funds in the Treasury not otherwise appropriated, there are authorized to be appropriated, and there are appropriated, to the Fund, $500,000,000 for the second calendar quarter of fiscal year 2022. (e) Amount of award The amount of an award to a center of excellence under subsection (a) shall be not less than $10,000,000 for the first calendar quarter of fiscal year 2022, and $5,000,000 for each of fiscal years 2023, 2024, 2025, 2026, and 2027. (f) Condition Each center of excellence shall, as a condition of receipt of funds under subsection (a), submit to the Secretary a budget that describes the activities to be funded under the award, which may include the purchasing of equipment, costs related to construction, and other such activities that contribute to the center’s ability to address the issues described in subsection (a) and to address and prepare for future pandemics. (g) Reporting process An entity that receives an award under this section shall work with an office within the Department of Health and Human Services, as designated by the Secretary, to submit annual progress reports and other such annual reports determined necessary by the Secretary. (h) Distribution In awarding grants under this section, the Secretary shall, to the extent practicable, ensure an equitable national geographic distribution of the grants, contracts, or cooperative agreements, including areas of the United States where the incidence of COVID–19 cases or cases of a disease responsible for a subsequent pandemic, is highest. (i) Advisory committee reporting Not later than 1 year after the date of enactment of this Act, and every year thereafter, the advisory committee established under subsection (c) shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report which shall include a synthesized analysis of all Centers of Excellence grantees findings, best practices determined for each item specified under paragraphs (1) and (2) of subsection (a), policy recommendations, and other reports determined necessary by the Secretary. (j) Academic medical center defined In this section, the term academic medical center means— (1) an institutition with— (A) integrated health care delivery; (B) medical education and training; and (C) basic, clinical, translational, and implementation research operations; and (2) an institution that meets such other criteria as the Secretary may establish.